Clinical and Imaging Features in MRKH Syndrome (ROK-US)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Not yet enrolling

Conditions: Mayer Rokitansky Kuster Hauser Syndrome; Müllerian Agenesis

Study type: Observational

Funder types: Other

Identifiers

NCT07321782

8153

Details and patient eligibility

About

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a congenital condition characterized by uterovaginal agenesis in phenotypically normal women with a 46,XX karyotype. Despite increasing knowledge of its clinical and genetic features, MRKH syndrome shows marked phenotypic heterogeneity, and current classification systems do not fully reflect the wide spectrum of anatomical presentations encountered in clinical practice.

This ambispective, observational, monocenter study aims to describe the clinical, sonographic, radiological, and genetic characteristics of patients with suspected or confirmed MRKH syndrome referred to a tertiary referral center. All enrolled patients will undergo standardized pelvic ultrasound evaluation, including transabdominal and transrectal approaches, with optional MRI according to clinical indications. Sonovaginography will be performed to objectively assess vaginal length. Genetic investigations, including array CGH and next-generation sequencing, will be conducted as part of routine clinical care.

The primary objective is to characterize the clinical and ultrasound features of MRKH syndrome. Secondary objectives include the development of a novel image-based classification system to better describe disease severity and morphological patterns, validation of sonovaginography for vaginal length measurement, and correlation of genetic alterations with ultrasound-based staging. The study aims to improve diagnostic standardization and contribute to a better understanding of the genotype-phenotype relationship in MRKH syndrome.

Enrollment: 25 estimated patients

Sex: Female

Ages: 10 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Female patients with suspected or previously diagnosed MRKH syndrome
• 46,XX karyotype
• Age 10-60 years
• For prospective patients: signed Informed Consent and Consent to Data Processing (by patient or parent/guardian if minor)
• For retrospective patients: availability of data collected in compliance with Data Protection regulations (DPIA conducted)

Exclusion Criteria

• Patients with other causes of primary amenorrhea (e.g., Androgen Insensitivity Syndrome / Morris syndrome)
• Karyotype different from 46,XX
• For prospective patients: inability to provide informed consent or parental/guardian consent if minor